WeVote
Log In

Bill

Bill

HB 1154

INSURANCE: Prohibits prior authorizations requirements for certain generic medications prescribed by qualified physicians (EN NO IMPACT GF EX See Note)

2026 Regular Session Introduced by Beryl Amedée and 13 co-sponsors

Prohibits prior authorization for certain low-cost non-opioid generics when prescribed by eligible board-certified physicians, speeding access and reducing hurdles.

Effective date: See Act.
0
WeVote Research Nonpartisan
Bill Summary · HB 1154

Summary of HB 1154 (Louisiana, 2026 Regular Session)

Primary purpose

HB 1154 aims to prohibit prior authorization requirements for certain generic medications when prescribed by qualified physicians, specifically in the contexts of commercial insurance plans and Medicaid managed care organizations. The underlying goal is to reduce administrative hurdles and speed access to affordable generic medications.

Key provisions and changes

  • Definitions added/modified

    • Introduces terms relevant to the bill: board-certified physician, commercial insurer, generic medication, and prior authorization.
    • Keeps existing law definitions in place where applicable and clarifies meanings within the new framework.

  • Commercial insurers (non-Medicaid)

    • Prohibits commercial insurers from requiring prior authorization for certain generic medications when:
    • The medication is not an opioid, and
    • It is prescribed by a board-certified physician whose specialty certification includes the medical indication for which the drug is prescribed, and
    • The Wholesale Acquisition Cost (WAC) is no more than $250 per prescription (added by amendments).
    • Effectively, non-opioid generics with low-cost per prescription can be dispensed without prior authorization if prescribed by an appropriately credentialed physician.

  • Medicaid managed care organizations

    • Prohibits Medicaid managed care organizations from requiring prior authorization for certain generic medications when prescribed by:
    • A board-certified physician whose specialty certification includes the medical indication for which the drug is prescribed, or
    • An authorized provider (as defined in amendments).
    • This creates a similar streamlined access pathway for Medicaid beneficiaries, subject to the specialty indication alignment.

  • Scope of application and conversion timeline

    • Applies to new policies, contracts, health coverage plans, or Medicaid managed care issued on or after January 1, 2027.
    • For plans in effect prior to January 1, 2027: they must conform to the new provisions by their renewal date, but no later than January 1, 2028.

  • Statutory additions

    • Adds new subsections to Louisiana Revised Statutes (R.S. 22:1060.1(9)-(12) and 1060.9) and R.S. 46:153.3.3 to reflect these rules.

Who is affected

  • Patients enrolled in commercial insurance plans for whom the prescribed generic medication meets the bill’s criteria (non-opioid, WAC ≤ $250, board-certified physician with relevant specialty).
  • Medicaid beneficiaries enrolled in managed care organizations where the prescriber is a board-certified physician (or authorized provider) with the correct specialty indication.
  • Prescribers: board-certified physicians (and authorized providers) whose specialty aligns with the medication’s indication.
  • Insurers and Medicaid managed care organizations: subject to new prior authorization prohibitions for eligible generics.

Significant procedural/timeline aspects

  • Effective date for new policies/plans: January 1, 2027.
  • Transition for existing plans: Pre-2027 plans must convert to conform by their renewal date, but no later than January 1, 2028.
  • Amendments added by the House Insurance Committee:
    • Non-opioid generics with WAC ≤ $250 per prescription are exempt from prior authorization when prescribed by eligible physicians.
    • Authorized providers may be included for Medicaid managed care authorization flexibility.
    • Technical clarifications to terminology and applicability.

Practical impact

  • Potentially faster access to low-cost generic medications for patients, reducing administrative delays.
  • Possible administrative cost savings for insurers and Medicaid programs by removing routine prior authorization for targeted generics.
  • Encourages use of board-certified physicians whose specialty aligns with the indicated use of the prescribed medication.

Note: The bill contains amendments that refine the scope (notably the $250 WAC threshold for non-opioids and inclusion of authorized providers for Medicaid) and clarifies applicability.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.